Zhejiang Jingshen Pharmaceutical Co., Ltd.
Independent Director 2025 Annual Report of Duties
As an independent director of Zhejiang Jingshen Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company"), in accordance with the provisions of relevant laws and regulations such as the Company Law, the Corporate Governance Guidelines for Listed Companies, the Shenzhen Stock Exchange Main Board Listed Company Standard Operation Guide No. 1, and the Administrative Measures for Independent Directors of Listed Companies, as well as the requirements of the Articles of Association and the Work System for Independent Directors, I have always maintained loyalty, diligence, and independence in performing my duties. I have actively attended the Company's relevant meetings in 2025, diligently reviewed all proposals submitted to the Board of Directors, and fully exercised the role of an independent director to effectively protect the interests of the Company and all shareholders, especially small and medium shareholders. The following is a report on my performance of duties in 2025:
I. Basic Information of Independent Director
Xu Pan, with a doctoral degree, is a Certified Public Accountant in China and an internationally registered internal auditor. He currently serves as a specially appointed deputy director of the Academic Affairs Office and an associate professor at the School of Management of Zhejiang University of Technology. He has served as an independent director of the Company since October 2022.
During the reporting period, I conducted a self-assessment of my independence and concluded that there are no circumstances affecting my independence, and I meet the independence requirements stipulated in Article 6 of the Administrative Measures for Independent Directors of Listed Companies.
II. Attendance at Board of Directors and Shareholders' Meetings
In 2025, as an independent director of the Company, I diligently performed my duties in strict accordance with the requirements of laws, regulations, and rules. There were no instances of absence from meetings that I was required to attend. In 2025, the Company held a total of 9 Board of Directors meetings and 3 Shareholders' meetings during my term. The convening and holding of these meetings complied with legal procedures, and major operational decisions and other significant matters were handled through relevant procedures, making them legal and effective. In 2025, I did not raise any objections to any proposals of the Board of Directors or other matters of the Company.
- In 2025, my attendance at meetings was as follows:
| Name | Number of Board Meetings to Attend | Number of Personally Attended Board Meetings | Number of Entrusted Attendance | Voting Record (Number of Against Votes) | Whether Absent from Board Meetings for Two Consecutive Times |
|---|---|---|---|---|---|
| Xu Pan | 9 | 8 | 1 | 0 | No |
- I voted in favor of all proposals reviewed at the Board of Directors meetings.
- There were no instances of absence from Board meetings.
- In 2025, the Company held 3 Shareholders' meetings during my term, and I did not attend any of them.
III. Work of Board Committees and Independent Director Special Meetings
In 2025, I served as the Chairman of the Audit Committee of the Board of Directors, and a member of the Strategy Committee, Nomination Committee, and Remuneration and Assessment Committee. I exercised my powers and fulfilled my duties in strict accordance with relevant regulations.
In 2025, the Company held 4 Audit Committee meetings, 3 Nomination Committee meetings, 2 Remuneration and Assessment Committee meetings, 1 Strategy Committee meeting, and 1 Independent Director Special Meeting. I personally attended all these meetings and reviewed proposals related to the Company's annual reports, qualifications of senior management, remuneration of senior management, employee stock ownership plans, and the Company's operational plans. I diligently performed the duties of the Board committees and the Independent Director Special Meeting.